TriangleNCT01327612 · OUTCOME
Maximum Change From Baseline in Blood Pressure
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- mmHg
- Interval / dispersion
- Standard Deviation
- Time frame
- Baseline and day 1 of each treatment cycle (every 2, 3, or 4 weeks depending on dosing schedule) up to 30 days after last dose; median duration of treatment with conatumumab was 1190.5 days and 1163.0 days for ganitumab.
What was measured
Maximum change from baseline is defined for each participant as the maximum change from baseline value observed across all visits.
Analysis population: Participants who received at least one dose of conatumumab or ganitumab.
Groups in this outcome
20050118: Ganitumab 20 mg/kg
Ganitumab 20 mg/kg once every 4 weeks by intravenous infusion.
20050171: Conatumumab 0.45 mg/kg
Conatumumab 0.45 mg/kg every 2 weeks by intravenous infusion.
20060295: Conatumumab 3 mg/kg
Conatumumab 3 mg/kg every 3 weeks by intravenous infusion.
20060340: Conatumumab 5 mg/kg
Conatumumab 5 mg/kg once every 3 weeks by intravenous infusion.
20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab
Conatumumab 2 mg/kg once every 2 weeks by intravenous infusion in addition to modified FOLFOX6 chemotherapy and bevacizumab 5 mg/kg once every 2 weeks.
20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab
Conatumumab 10 mg/kg once every 2 weeks by intravenous infusion in addition to modified FOLFOX6 chemotherapy, with or without bevacizumab 5 mg/kg once every 2 weeks.
20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg
Conatumumab 15 mg/kg + ganitumab 18 mg/kg once every 3 weeks by intravenous infusion.
| Group | Source count |
|---|---|
| 20050118: Ganitumab 20 mg/kg | 2 |
| 20050171: Conatumumab 0.45 mg/kg | 1 |
| 20060295: Conatumumab 3 mg/kg | 1 |
| 20060340: Conatumumab 5 mg/kg | 1 |
| 20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab | 2 |
| 20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab | 3 |
| 20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg | 2 |
Reported measurements
Systolic blood pressure
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| 20050118: Ganitumab 20 mg/kg | 5.5 | 9.2 | Not reported | Not reported | Not reported |
| 20050171: Conatumumab 0.45 mg/kg | 7.0 | Not reported | Not reported | Not reported | Not reported |
| 20060295: Conatumumab 3 mg/kg | 54.0 | Not reported | Not reported | Not reported | Not reported |
| 20060340: Conatumumab 5 mg/kg | 37.0 | Not reported | Not reported | Not reported | Not reported |
| 20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab | 42.0 | 0.0 | Not reported | Not reported | Not reported |
| 20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab | 26.0 | 17.3 | Not reported | Not reported | Not reported |
| 20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg | 32.5 | 31.8 | Not reported | Not reported | Not reported |
Diastolic blood pressure
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| 20050118: Ganitumab 20 mg/kg | 7.5 | 9.2 | Not reported | Not reported | Not reported |
| 20050171: Conatumumab 0.45 mg/kg | 1.0 | Not reported | Not reported | Not reported | Not reported |
| 20060295: Conatumumab 3 mg/kg | 10.0 | Not reported | Not reported | Not reported | Not reported |
| 20060340: Conatumumab 5 mg/kg | 13.0 | Not reported | Not reported | Not reported | Not reported |
| 20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab | 27.5 | 9.2 | Not reported | Not reported | Not reported |
| 20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab | 14.7 | 6.4 | Not reported | Not reported | Not reported |
| 20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg | 23.5 | 6.4 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 9.2
- value
- 5.5
- group Id
- OG001
- value
- 7.0
- group Id
- OG002
- value
- 54.0
- group Id
- OG003
- value
- 37.0
- group Id
- OG004
- spread
- 0.0
- value
- 42.0
- group Id
- OG005
- spread
- 17.3
- value
- 26.0
- group Id
- OG006
- spread
- 31.8
- value
- 32.5
- title
- Systolic blood pressure
- categories
- measurements
- group Id
- OG000
- spread
- 9.2
- value
- 7.5
- group Id
- OG001
- value
- 1.0
- group Id
- OG002
- value
- 10.0
- group Id
- OG003
- value
- 13.0
- group Id
- OG004
- spread
- 9.2
- value
- 27.5
- group Id
- OG005
- spread
- 6.4
- value
- 14.7
- group Id
- OG006
- spread
- 6.4
- value
- 23.5
- title
- Diastolic blood pressure
- denoms
- counts
- group Id
- OG000
- value
- 2
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 1
- group Id
- OG004
- value
- 2
- group Id
- OG005
- value
- 3
- group Id
- OG006
- value
- 2
- units
- Participants
- description
- Maximum change from baseline is defined for each participant as the maximum change from baseline value observed across all visits.
- dispersion Type
- Standard Deviation
- groups
- description
- Ganitumab 20 mg/kg once every 4 weeks by intravenous infusion.
- id
- OG000
- title
- 20050118: Ganitumab 20 mg/kg
- description
- Conatumumab 0.45 mg/kg every 2 weeks by intravenous infusion.
- id
- OG001
- title
- 20050171: Conatumumab 0.45 mg/kg
- description
- Conatumumab 3 mg/kg every 3 weeks by intravenous infusion.
- id
- OG002
- title
- 20060295: Conatumumab 3 mg/kg
- description
- Conatumumab 5 mg/kg once every 3 weeks by intravenous infusion.
- id
- OG003
- title
- 20060340: Conatumumab 5 mg/kg
- description
- Conatumumab 2 mg/kg once every 2 weeks by intravenous infusion in addition to modified FOLFOX6 chemotherapy and bevacizumab 5 mg/kg once every 2 weeks.
- id
- OG004
- title
- 20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab
- description
- Conatumumab 10 mg/kg once every 2 weeks by intravenous infusion in addition to modified FOLFOX6 chemotherapy, with or without bevacizumab 5 mg/kg once every 2 weeks.
- id
- OG005
- title
- 20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab
- description
- Conatumumab 15 mg/kg + ganitumab 18 mg/kg once every 3 weeks by intravenous infusion.
- id
- OG006
- title
- 20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg
- param Type
- MEAN
- population Description
- Participants who received at least one dose of conatumumab or ganitumab.
- reporting Status
- POSTED
- time Frame
- Baseline and day 1 of each treatment cycle (every 2, 3, or 4 weeks depending on dosing schedule) up to 30 days after last dose; median duration of treatment with conatumumab was 1190.5 days and 1163.0 days for ganitumab.
- title
- Maximum Change From Baseline in Blood Pressure
- type
- SECONDARY
- unit Of Measure
- mmHg
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice